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Introduction {#sec005}
============

In contrast to epidemiological studies on age related macular degeneration (AMD), there are very few studies on population-based data on polypoidal choroidal vasculopathy (PCV) due to the inherent difficulty of diagnosing the disease from fundus photographs alone \[[@pone.0231901.ref001]\]. Thus, the estimates of PCV prevalence can only be accurately derived from hospital based cross-sectional studies. These studies have shown a prevalence of 4% \[[@pone.0231901.ref002]\] to 54% \[[@pone.0231901.ref003]\] depending on the inclusion criteria, imaging modality and ethnic origin of the population. The prevalence of PCV is known to be higher in Afro-Caribbean cohort and Eastern Asia population and low in the white race \[[@pone.0231901.ref004]\].

Although PCV has characteristic optical coherence tomography (OCT) features, indocyanine green angiography (ICGA) remains the definitive diagnostic imaging modality for PCV \[[@pone.0231901.ref005]\]. We have previously reported the prevalence of early or intermediate AMD to be \~ 21% in the rural Indian population and \~ 16% in the urban Indian population aged 60 years or more based on color fundus photographs. Likewise, the prevalence of neovascular AMD is \~ 2% in the same rural and urban Indian populations \[[@pone.0231901.ref006]\]. However, ICGA was not done in any population-based studies from India and so the prevalence of PCV in India is unclear. The aim of the study was to elucidate the prevalence, demography, risk factors and imaging characteristics of PCV in a hospital-based South Indian population presenting with characteristic features of neovascular AMD.

Methods {#sec006}
=======

All patients aged 40 years or above who presented with presumed neovascular AMD to the Vitreoretinal services of a tertiary eye care center in South India from January to December 2016 were reviewed from the electronic medical records (EMR). Institutional review board approval (Ethics Committee, Vision Research Foundation) was obtained for this retrospective study. It is the hospital protocol to obtain informed consent form before any procedure including invasive procedure such as ICGA and FFA. The informed consent includes the information on how data will be used for scientific research and will be anonymized. The EMR was searched using the following keywords that defined the presenting diagnosis: choroidal neovascular membrane, wet age-related macular degeneration, hemorrhagic pigment endothelial detachment, polyps and ICD coding for polypoidal choroidal vasculopathy. All these entities represent the spectrum of serosanguinous maculopathy. Those with clinical suspicion of PCV, that is presence of subretinal exudation, subretinal hemorrhage, presence of pigment epithelial detachment, serous neurosensory detachment, peripapillary location, multiple lesions and visible polyps, underwent multimodal imaging. Multimodal imaging included color fundus photograph (Visupac, Version 4.4.3, Carl Zeiss Meditec.), fundus fluorescein angiography (FFA), ICGA (HRA system; Heidelberg Engineering, Heidelberg, Germany and visupac, Version 4.4.3, Carl Zeiss Meditec) and OCT (Cirrus OCT-Carl Zeiss Meditec, Dublin, CA, USA, Spectralis OCT- HRA system; Heidelberg Engineering, Heidelberg, Germany, Swept Source OCT-- 3D Optical Coherence tomography: DRI OCT-1 Atlantis, Topcon 3D OCT 2000-Toyko,Japan.). The extracted images were deidentified.

Clinical presentations of PCV {#sec007}
-----------------------------

The clinical presentations were graded as (1) predominantly hemorrhagic pattern defined as presence of hemorrhagic pigment epithelial detachment (PED), submacular hemorrhage and multiple layers of hemorrhage, or (2) exudative pattern defined as the presence of exudates with serous or serosanguinous PED and/or subretinal fluid or (3) mixed lesions defined as the presence of both hemorrhagic and exudative features.

Multimodal imaging diagnosis of PCV {#sec008}
-----------------------------------

The diagnosis of PCV on colour photographs FFA and ICGA were confirmed based on the EVEREST criteria \[[@pone.0231901.ref007]\] that included the presence of early sub-retinal focal hyperfluorescence on ICGA (within the first 6 min), and at least one of the following criteria: (1) nodular appearance of the polyp(s) on stereoscopic examination, (2) hypofluorescent halo around the nodule(s), (3) presence of a branching vascular network (BVN), (4) pulsation of the polyp(s) on dynamic ICGA, (5) orange sub-retinal nodules on color fundus photography that corresponded to the ICGA nodules, or (6) massive sub-macular hemorrhage (≥4 disc areas in size). Definitive polyp was defined as the presence of aneurysmal dilation clearly demarked in ICGA as minute hyperfluorescence. When the appearance of minute hyperfluorescence or aneurysmal dilation was masked due to hemorrhage or media haze and there was diffuse hyperfluorescence suggestive of an underlying polyp, the term suspicious polyp was used. Choroidal neovascularization (CNVM) due to AMD was diagnosed if the lesion showed presence of subretinal hemorrhage, subretinal fluid and retinal pigment epithelium(RPE) alterations with occult, ill-defined choroidal neovascularization lesion on FFA and early hyperfluorescence spots or plaque like hyperfluorescence in ICGA along with the absence of polyp and abnormal branching vascular network. Likewise, those who had features of different stages of retinal angiomatous proliferans (RAP) as described by Yannuzzi et al \[[@pone.0231901.ref008]\] were also excluded.

Specific lesion characteristics of PCV {#sec009}
--------------------------------------

OCT and ICGA features of lesion characteristics were further defined as described as in the report by Anantharaman et al \[[@pone.0231901.ref009]\] and is shown in [Fig 1](#pone.0231901.g001){ref-type="fig"}. BVN (Branching vascular network) was defined on early phase of the ICGA (first 1 min) as a distinct network of vessels within the choroid termed as branching vascular network. Polyp was defined as small hyperfluorescent spots, isolated or in clusters that become visible soon after the PCV network is discernible on the ICGA. Early nodular hyperfluorescence arising from choroidal circulation noted within the first 6 min of dye injection were termed polyp. The polyps also leak slowly as the surrounding hitherto hypofluorescent area becomes increasingly hyper-fluorescence. Choroidal hyperpermeability was defined on mid phase ICGA as multiple and patchy choroidal hyperfluorescence.

![Definitions used in the classification of features.](pone.0231901.g001){#pone.0231901.g001}

### Speckled hyperfluorescence {#sec010}

Mid phase multiple and patchy choroidal hyperfluorescence, indicating choroidal hyperpermeability.

Late-onset focal hyperfluorescent lesion with clear margin apparent with rosette pattern after at least 6 minutes phase of ICGA was termed as hyperfluorescence foci. OCT characteristics included peak-like PED defined as a sharp peak like elevation seen in PED with underlying moderate reflectivity. A tomographic notch was defined as a V-shaped dip between two PED and a double layer sign (DLS) was defined as a separation of RPE layer from underlying Bruch's membrane containing neovascular complex.

Accuracy of grading {#sec011}
-------------------

The extracted images were deidentified and were assessed by 2 senior retina specialists (with more than 10 years retinal experience) independently in a masked manner. An adjudicated grade by a third senior retina specialist was considered as a final diagnosis in cases where the diagnosis differed between the two retina specialists.

Statistical analysis {#sec012}
--------------------

Statistical analysis was performed using statistical software (SPSS for windows, Version 20, SPSS science, IBM, Chicago, Illinois, USA). The results were expressed in frequencies for categorical data and percentage for continuous data. Chi square test was done to compare proportions in PCV and CNVM group. RAPs were excluded from comparative analysis due to the small numbers. Univariate logistic regression analysis was performed to assess risk factors for PCV. Kappa statistics was done to report intergrader agreement.

Results {#sec013}
=======

Of the 785 records that matched with the keywords searched, 147 patients underwent multimodal imaging due to clinical suspicion of PCV. The proportions of patients with PCV, CNVM and RAP based on clinical presentations are shown in [Fig 2](#pone.0231901.g002){ref-type="fig"}. The prevalence of PCV among serosanguinous maculopathy was found to be 49.7% ([Fig 2](#pone.0231901.g002){ref-type="fig"}). The overall prevalence of PCV was 9.29%. The kappa agreement between the graders was k = 0.632 (p = 0.001).

![Flow of patient search and grading process.](pone.0231901.g002){#pone.0231901.g002}

[Table 1](#pone.0231901.t001){ref-type="table"} shows the demographic, systemic and ocular features of PCV. The prevalence of PCV increased with increasing age with a maximum (38.4%) in 70--80 years age group. PCV showed a unilateral preponderance (82.2%) and the majority were located in the macula (64.4%). The clinical presentation included hemorrhagic (52.1%), followed by exudative (34.25%) and mixed (13.70%). History of hypertension, ischemic heart disease were less prevalent in PCV.

10.1371/journal.pone.0231901.t001

###### Prevalence of PCV in different subgroups.

![](pone.0231901.t001){#pone.0231901.t001g}

  Variable                                                                   n    Prevalence   95%CI            p
  -------------------------------------------------------------------------- ---- ------------ ---------------- ----------
  **Age (years)**                                                                                               
  40--50                                                                     8    10.95%       (5.66--20.66)    **0.00**
  50--60                                                                     11   15.06%       (8.63--25.00)    
  60--70                                                                     28   38.35%       (28.05--49.83)   
  70 and above                                                               26   36.99%       (26.82--48.45)   
  **Gender**                                                                                                    
  Male                                                                       38   52.05%       (40.78--63.12)   0.725
  Female                                                                     35   47.95%       (36.87--59.21)   
  **Laterality**                                                                                                
  Unilateral                                                                 60   82.20%       (71.88--89.29)   **0.00**
  Bilateral                                                                  13   17.80%       (10.71--28.12)   
  **Location**                                                                                                  
  Macular                                                                    47   64.38%       (52.93--74.41)   **0.00**
  Extra-macular                                                              11   15.07%       (8.63--25.00)    
  Peripapillary                                                              6    8.22%        (3.82--16.79)    
  Mixed                                                                      9    12.33%       (6.62--21.80)    
  **PCV**[\*](#t001fn001){ref-type="table-fn"} **Type**                                                         
  Exudative                                                                  25   34.25%       (24.39--45.67)   **0.00**
  Hemorrhagic                                                                38   52.10%       (40.78--63.12)   
  Mixed                                                                      10   13.70%       (7.61--23.41)    
  **Presence of Systemic disease**                                                                              
  **H/o**[^†^](#t001fn002){ref-type="table-fn"} **Diabetic mellitus**                                           
  Present                                                                    30   58.90%       (47.44--69.46)   0.13
  Absent                                                                     43   41.10%       (30.53--52.55)   
  **H/o**[^†^](#t001fn002){ref-type="table-fn"} **Hypertension**                                                
  Present                                                                    37   50.68%       (39.47--61.83)   0.907
  Absent                                                                     36   49.32%       (38.17--60.53)   
  **H/o**[^†^](#t001fn002){ref-type="table-fn"} **Ischemic heart disease**                                      
  Present                                                                    9    12.33%       (6.62--21.80)    **0.00**
  Absent                                                                     64   87.67%       (78.20--93.38)   
  **H/o**[^†^](#t001fn002){ref-type="table-fn"} **Hypercholesterolemia**                                        
  Present                                                                    9    9.59%        (4.72--18.50)    **0.00**
  Absent                                                                     64   87.67        (78.20--93.38)   

\*PCV: Polypoidal Choroidal vasculopathy,

^†^H/o: History.

[Table 2](#pone.0231901.t002){ref-type="table"} shows the univariate and multivariate analysis of risk factors for PCV. No statistical significance was achieved.

10.1371/journal.pone.0231901.t002

###### Univariate and multivariate analysis for risk factors for PCV.

![](pone.0231901.t002){#pone.0231901.t002g}

  Variable                     Univariate           Multivariate                         
  ---------------------------- -------------------- -------------- --------------------- -------
  Gender                       1.59(0.810--3.038)   0.18           1.59(0.812--3.11)     0.174
  H/o Diabetic mellites        1.51(0.769--2.991)   0.229          1.44(0.695--2.995)    0.325
  H/o Hypertension             1.31(0.687--2.52)    0.408          1.198(0.608--2.364)   0.601
  H/o Ischemic heart disease   1.00(0.873--2.683)   1              0.899(0.320--2.528)   0.84
  H/o Hypercholesterolemia     1.83(0.512--6.54)    0.353          1.44(0.390--5.634)    0.598

PCV: Polypoidal choroidovasculopathy, H/o: History, OR: Odds ratio.

52.10% of PCV patients presented with hemorrhagic pattern, 34.25% showed exudative and 13.70% were of mixed subtype. [Fig 3](#pone.0231901.g003){ref-type="fig"} shows the frequency of clinical findings present on fundus photographs. Most common feature was the presence of subretinal hemorrhage (71.2%) followed by PED (37%). Definitive clinically polyp was visible in 9.6% cases and suspicious polyps were present in 10.9% cases. No pulsation of polyp was observed in these cases.

![The proportions of patients with PCV, CNVM and RAP in each clinical category.](pone.0231901.g003){#pone.0231901.g003}

[Table 3](#pone.0231901.t003){ref-type="table"} shows the FFA and ICGA features of patients with PCV. The presence of BVN was noted in 58% of the PCV patients and it was maximum in hemorrhagic type of PCV. However statistically significant differences in the presence of BVN were not observed in the three types of PCV. Polyps were single in 34.3% cases, multiple in 39.7% and in cluster in17.8% cases. The occurrence of speckled hyperfluorescence was seen in 54.8% cases, however it was not statistically significant across the groups. The presence of hyperfluorescent foci was noted only in 17.8% of the PCV cases.

10.1371/journal.pone.0231901.t003

###### Fundus fluorescein and Indocynanine green angiogram features in patients with PCV.

![](pone.0231901.t003){#pone.0231901.t003g}

  Feature                                        Exudative (N = 25)   Hemorrhagic (N = 38)   Mixed (N = 10)   p            Overall (N = 73)
  ---------------------------------------------- -------------------- ---------------------- ---------------- ------------ ------------------
  **BVN**[\*](#t003fn001){ref-type="table-fn"}                                                                             
  Present                                        13 (52%)             22 (58%)               7 (70%)          0.62         42 (58%)
  Absent                                         12 (48%)             16 (42%)               3 (30%)          31 (42%)     
  **Polyp**                                                                                                                
  None                                           2 (8%)               3 (7.9%)               1 (10%)          0.09         6 (8.2%)
  Single                                         9 (36%)              13 (34.2%)             3 (30%)          25 (34.3%)   
  Multiple                                       9 (36%)              17 (44.7%)             3 (30%)                       29 (39.7%)
  Cluster                                        5 (20%)              5 (13.2%)              3 (30%)                       13 (17.8%)
  **Speckled hyperfluorescence**                                                                                           
  Present                                        11 (44%)             21 (55.3%)             8 (80%)          0.15         40 (54.8%)
  Absent                                         14 (56%)             17 (44.7%)             2 (20%)          33 (45.2%)   
  **Hyperfluorescence foci**                                                                                               
  Present                                        5 (20%)              7 (18.4%)              1 (10%)          0.78         13 (17.8%)
  Absent                                         20 (80%)             31 (81.6%)             9 (90%)          60 (82.2%)   

\*BVN: Branching vascular network.

[Table 4](#pone.0231901.t004){ref-type="table"} shows the OCT characteristics of PCV across the three subtypes. Peaked PED was seen in 67.1%, tomographic notch in 68.5%- and double-layer sign in 61.6% of the cases. There were no statistically significant differences in the distribution of these features in the clinical subtypes of PCV.

10.1371/journal.pone.0231901.t004

###### OCT features in the patients with PCV.

![](pone.0231901.t004){#pone.0231901.t004g}

  Feature                                                   Exudative (N = 25)   Hemorrhagic (N = 38)   Mixed (N = 10)   p           Overall (N = 73)
  --------------------------------------------------------- -------------------- ---------------------- ---------------- ----------- ------------------
  **PED**[\*](#t004fn001){ref-type="table-fn"}                                                                                       
  None                                                      0 (0%)               1 (2.6%)               0 (0%)                       1 (1.4%)
  Fibrovascular PED[\*](#t004fn001){ref-type="table-fn"}    8 (32%)              5 (13.2%)              3 (30%)          0.093       16 (21.9%)
  Hemorrhagic PED[\*](#t004fn001){ref-type="table-fn"}      2 (8%)               14 (36.8%)             1 (10%)                      17 (23.3%
  Serosanguinous PED[\*](#t004fn001){ref-type="table-fn"}   15 (60%)             18 (47.4%)             6 (60%)                      39 (53.4%)
  **SRF**[^†^](#t004fn002){ref-type="table-fn"}                                                                                      
  Present                                                   20 (80%)             35 (92.1%)             9 (90%)                      64 (87.7%)
  Absent                                                    5 (20%)              3 (7.9%)               1 (10%)          0.35        9 (12.3%)
  **SRH**[^‡^](#t004fn003){ref-type="table-fn"}                                                                                      
  Present                                                   10 (40%)             29 (76.3%)             8 (80%)          **0.007**   47 (6.4%)
  Absent                                                    15 (60%)             9 (23.7%)              2 (20%)                      26 (93.6%)
  **Peaked PED**[\*](#t004fn001){ref-type="table-fn"}                                                                                
  Present                                                   16(64%)              27(71.05%)             6(60%)           0.735       49 (67.1)%
  Absent                                                    9(36%)               11(28.95%)             4(40%)                       24 (32.8%)
  **Tomographic notch**                                                                                                              
  Present                                                   18(72.5)             26(68.4%)              6(60%)           0.785       50 (68.5%)
  Absent                                                    7(28%)               12(31.6%)              4(40%)                       23 (31.5%)
  **Double Layer sign**                                                                                                              
  Present                                                   13(52%)              24(63.1%)              8(80%)                       45 (61.6%)
  Absent                                                    12(48%)              14(36.8%)              2(20%)           0.294       28 (38.4%)

\*PED: Pigment epithelial detachment,

^†^SRF: Subretinal fluid,

^‡^SRH: Subretinal hemorrhage,

Discussion {#sec014}
==========

We report the prevalence of clinical and imaging characteristics of PCV in an Indian population seen within a tertiary center in South India. The prevalence of PCV among patients with serosanguinous maculopathy was found to be 49.7%, overall prevalence being 9.29% and is comparable to other clinic-based population studies conducted in Asia and Europe population.

[Table 5](#pone.0231901.t005){ref-type="table"} shows the summary of hospital and population- based studies across different population. Similar to our study, majority of the studies are hospital- based studies. The prevalence of PCV is lower in studies from US \[[@pone.0231901.ref005]\] and Europe \[[@pone.0231901.ref002],[@pone.0231901.ref010],[@pone.0231901.ref011]\] compared to studies from Asia. \[[@pone.0231901.ref004],[@pone.0231901.ref012],[@pone.0231901.ref013]--[@pone.0231901.ref015],[@pone.0231901.ref016]\] It is unknown why such ethnic variation exists in the epidemiology of PCV. Although a genetic predisposition may explain racial differences \[[@pone.0231901.ref017]\], it is unclear why the deeper choroidal vessels are more affected in Asian and Afrocarribean populations compared to the choriocapillaris in the white races. Further studies on differences in scleral resistance, vortex vein and choroidal vasculature may provide clues to explain these differences.

10.1371/journal.pone.0231901.t005

###### Comparing the prevalence of PCV across various studies.

![](pone.0231901.t005){#pone.0231901.t005g}

  Author                                                     Year   Country    Mean age (years)   Diagnosis tools used                                                                                                                                                          Study Population   N          Unilateral%   Prevalence
  ---------------------------------------------------------- ------ ---------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ---------- ------------- ------------
  Yannuzzi et al \[[@pone.0231901.ref005]\]                  1999   USA        74.4               ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     167        46.2          7.80%
  Lafaut et al \[[@pone.0231901.ref002]\]                    2000   Belgium    NA                 FP[^†^](#t005fn002){ref-type="table-fn"}, FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}                                            Hospital based     374 eyes   39            4.00%
  Scassellati--sforzolini et al \[[@pone.0231901.ref010]\]   2001   Italy      70.2               FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                             Hospital based     194        78.9          9.80%
  Kwok et al \[[@pone.0231901.ref018]\]                      2002   China      65.1               ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     19         84.2          9.30%
  Sho et al \[[@pone.0231901.ref012]\]                       2003   Japan      68.4               FP[^†^](#t005fn002){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}                                                                                        Hospital based     418        90            23.92%
  Ladas et al \[[@pone.0231901.ref019]\]                     2004   Greece     72.5               ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     268        45.5          8.20%
  Wen et al \[[@pone.0231901.ref013]\]                       2004   China      68.3               FP[^†^](#t005fn002){ref-type="table-fn"},FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA                                                                                  Hospital based     166        86.5          22.30%
  Maruko et al \[[@pone.0231901.ref003]\]                    2007   Japan      NA                 ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     289        82.9          54.70%
  Liu et al \[[@pone.0231901.ref014]\]                       2007   China      65.4               FP[^†^](#t005fn002){ref-type="table-fn"},FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}                                             Hospital based     155        76.3          24.50%
  Beyon et al \[[@pone.0231901.ref015]\]                     2008   Korea      64.6               FP[^†^](#t005fn002){ref-type="table-fn"},FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}                                             Hospital based     79         75.9          24.60%
  Song et al \[[@pone.0231901.ref020]\]                      2009   Korea      57.2               FP[^†^](#t005fn002){ref-type="table-fn"},FFA[\*\*](#t005fn004){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}                                             Population based   10890      90            22.20%
  Li et al \[[@pone.0231901.ref021]\]                        2014   China      NA                 OCT[^‡^](#t005fn003){ref-type="table-fn"}                                                                                                                                     Population based   3468       94.1          0.30%
  Cackett et al \[[@pone.0231901.ref016]\]                   2010   China      68.3               ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     123        87.8          55.6%
  Bhoomibunchoo et al \[[@pone.0231901.ref004]\]             2017   Thailand   59.5               FP[^†^](#t005fn002){ref-type="table-fn"} and ICGA\*                                                                                                                           Hospital based     140        93            77.50%
  Yadav et al \[[@pone.0231901.ref011]\]                     2017   UK         75.4               ICGA[\*](#t005fn001){ref-type="table-fn"} features                                                                                                                            Hospital based     492        NA            9.14%
  Our study                                                  2018   India      65.3               FP[^†^](#t005fn002){ref-type="table-fn"},FFA[\*\*](#t005fn004){ref-type="table-fn"},OCT[^‡^](#t005fn003){ref-type="table-fn"} and ICGA[\*](#t005fn001){ref-type="table-fn"}   Hospital based     147        82.2          9.29%

\*ICGA:Indocyanine green angiogram,

^†^FP; fundus photo,

^‡^OCT: Optical coherence tomography,

\*\*FFA: Fundus fluorescein angiogram.

We found no difference in gender predilection between PCV and CNVM, similar to that reported by Yannuzzi et al \[[@pone.0231901.ref005]\] and Scassellati--sforzolini et al \[[@pone.0231901.ref010]\]. Previous reports indicate that PCV is more prevalent in men in Asian populations (22--37% female), but the opposite is observed in Caucasians (52--65% female). Differences in disease characterization and study design may explain our observation.

Surprisingly, we did not find a significant association of hypertension in PCV compared to CNVM group. The first literature is black ladies with hypertension \[[@pone.0231901.ref022]\].However, subsequent literature is conflicting. Ahuja et al \[[@pone.0231901.ref023]\] reported that 2.90% of their series had diabetes and 23.5% had a history of hypertension. Ladas et al \[[@pone.0231901.ref019]\] reported, 36.4% patients had a history of hypertension. Byeon et al \[[@pone.0231901.ref015]\] and Sho et al \[[@pone.0231901.ref012]\] in their series found that 31.65% and 36% had history of hypertension and 12.66% and 11% had a history of diabetes respectively. In our series 37 (50.68%) patients with PCV were hypertensive and 41.09% had history of diabetes. Given that hypertension is highly prevalent in this age group in the Asian population, an association of hypertension and PCV cannot be elucidated from small clinic-based studies.

Our study confirmed that macular polyps are more common in Asian population. PCVs were initially thought to occur in the peripapillary location. Subsequently, PCV lesions have been described in macular and mid periphery with ethnic variations. In our study, majority of polyps were macular (64.4%), followed by extra macular group 15.1%. Peripapillary polyps were found in only 8.2% of the eyes. Umaya et al \[[@pone.0231901.ref024]\] observed 94% polyps were macular and 9% were peripapillary in their study on 14 eyes. Anantharaman et al \[[@pone.0231901.ref009]\] also reported 45% being subfoveal 18% juxta foveal polyps and 18% peripapillary polyps in their study on 45 eyes in Indian patients. In contrast, studies from Europeans showed an equal distribution of macular and peripapillary location \[[@pone.0231901.ref025]\].

Our study showed that the prevalence increased with increasing age; majority being unilateral and macular. Hemorrhagic PCVs were slightly more common than the exudative subtypes. Sho et al \[[@pone.0231901.ref012]\] in his series reported 59% had exudative pattern and 30% had hemorrhagic pattern. Byeon et al \[[@pone.0231901.ref015]\] also reported higher rates of exudative pattern in 52% and hemorrhagic pattern in 34.7% of cases. Similar to our study, Bhoomibunchoo et al \[[@pone.0231901.ref004]\] reported hemorrhagic pattern to be 88.79% and exudative pattern in 11.21%. Uyama et al \[[@pone.0231901.ref024]\] and Ahuja et al \[[@pone.0231901.ref023]\] also reported higher percentage of hemorrhagic pattern which correlates with our study. We observed that the ICGA and OCT features of PCV do not statistically vary between the three main clinical presentations of PCV.

[Fig 4](#pone.0231901.g004){ref-type="fig"} shows that despite multiple modalities like FFA and OCT, ICG was the most helpful in diagnosis of PCV. The polyps were seen in 91.8% cases. However, features picked up on multimodal imaging collaborates in the diagnosis of PCV.

![Multiple modalities role in PCV diagnosis.](pone.0231901.g004){#pone.0231901.g004}

The merit of the present study is that it is the first study to examine the prevalence, risk factors and imaging characteristics of PCV in an Indian population from a tertiary center. However, our study also has several limitations. First, we may have introduced study sample selection bias because the study population was obtained from the EMR and only patients with multimodal imaging were selected. Our study results indicate that PCV may be present irrespective of the clinical presentation, suggesting that our study may have under-reported the prevalence of PCV. However, a prospective, multimodal imaging in a population-based prevalence study of PCV in an Indian population is not a feasible option.

Second, the possibility of potential bias in ascertaining history-related variables from EMR records should also be kept in mind; this was true particularly with regard to diabetes, hypertension and hypercholesteremia.

In conclusion, in the present study, we found that PCV is present in approximately half our study cohort and the prevalence, OCT and ICGA characteristics of PCV are similar irrespective of the clinical presentation. Therefore, multimodal imaging is recommended for all patients presenting with signs and symptoms of neovascular AMD.
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